Drug Trial Radar · NCT07124117
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
147
Planned (sponsor's estimate)
Start
Aug 4, 2025
Primary completion
Feb 8, 2029
Study completion Feb 8, 2029
Sponsor
- Lead sponsor
- OBI Pharma, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.
Conditions
- Advanced Solid Tumor
Interventions
OBI-902Drug
OBI-902 is an antibody-drug conjugate study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of OBI-902: incidence of adverse events (AEs) and serious adverse events (SAEs), changes in selected clinical laboratory parameters, cardiac parameters, and vital signs.Time frame: Duration of study, up to 54 weeks
- Maximum tolerated dose (MTD) of OBI-902Time frame: Duration of study, up to 54 weeks
- Preliminary antitumor activity of OBI-902 in selected tumor types - Objective Response Rate (ORR)Time frame: Duration of study, up to 54 weeks
- Preliminary antitumor activity of OBI-902 in selected tumor types - Duration of Response (DoR)Time frame: Duration of study, up to 54 weeks
- Preliminary antitumor activity of OBI-902 in selected tumor types - Clinical Benefit Rate (CBR)Time frame: Duration of study, up to 54 weeks
- Preliminary antitumor activity of OBI-902 in selected tumor types - Disease Control Rate (DCR)Time frame: Duration of study, up to 54 weeks
- Safety and tolerability of OBI-902 in Phase 1b/Phase 2: incidence of AEs, SAEs, and laboratory abnormalities.Time frame: Duration of study, up to 54 weeks
- Optimal recommended phase 2 dose (RP2D) of OBI-902Time frame: Duration of study, up to 54 weeks
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Scripps Green Hospital
La Jolla, California · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
China Medical University Hospital
Taichung, Taiwan · Recruiting
Wan Fan Hospital
Taipei, Wenshan, Taiwan · Recruiting
Shuang Ho Hospital
Taipei, Zhonghe, Taiwan · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.